First human trial for new drug ORKA-001 begins safety check
NCT ID NCT06698939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a single injection of ORKA-001 in 24 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The main goal was to check for side effects and changes in vital signs, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ORKA-001
- What could go wrong
- This is an early, small study in healthy people, so it cannot show if ORKA-001 works for any disease. Side effects are possible but unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oruka Therapeutics Investigative Site
Christchurch, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults